Drug intelligence / Profile preview

WSK-IM05

Development stage: Phase 1
Lead developer: WestVac Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

WSK-IM05 is a therapeutic HPV cancer vaccine developed by WestVac Biopharma for the treatment of oropharyngeal cancer caused by Human Papillomavirus (HPV) infection. It is distinguished as the first therapeutic HPV vaccine internationally to utilize an intranasal route of administration via a nasal spray. The vaccine is designed to elicit a mucosal and systemic immune response against HPV antigens associated with malignant tumors in the oropharynx. Currently in preclinical development, WSK-IM05 represents a novel approach to treating HPV-related malignancies through non-invasive delivery.

Beyond the preview

Go deeper on WSK-IM05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-IM05.

Explore the full profile